Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy

Fabian Zohren, Ingmar Bruns, Sabrina Pechtel, Thomas Schroeder, Roland Fenk, Akos Czibere, Georg Maschmeyer, Dorothea Kofahl-Krause, Norbert Niederle, Gerhard Heil, Christoph Losem, Manfred Welslau, Wolfram Brugger, Ulrich Germing, Ralf Kronenwett, Juergen Barth, Mathias J. Rummel, Rainer Haas, Guido Kobbe

Blood (2015) 126 (12): 1407–1414.

https://doi.org/10.1182/blood-2015-03-630012

Published: 2015

Includes: Supplemental data

Journal Articles

Subanalysis of the StiL NHL 1–2003 Study: Achievement of Complete Response with Bendamustine-Rituximab (B-R) and CHOP-R in the First-Line Treatment of Indolent and Mantle Cell Lymphomas Results in Superior Survival Compared to Partial Response.

Blood (2012) 120 (21): 2724.

https://doi.org/10.1182/blood.V120.21.2724.2724

Published: 2012

Journal Articles

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

Mathias J Rummel, MD, PhD, Ulrich Kaiser, MD, Christina Balser, Martina Beate Stauch, Wolfram Brugger, MD, PhD, Manfred Welslau, Norbert Niederle, Christoph Losem, Harald Ballo, Eckhart Weidmann, Ulrich von Gruenhagen, Lothar Mueller, Michael Sandherr, MD, Julia Vereschagina, Axel Hinke, Juergen Barth

Blood (2010) 116 (21): 856.

https://doi.org/10.1182/blood.V116.21.856.856

Published: 2010

Journal Articles

No Elevated Rates of Treatment-Related Myelodysplastic Syndromes and Second Solid Tumors Following Therapy with Bendamustine Compared with Other Anti-Lymphoma Regimes for Low-Grade Non-Hodgkin's Lymphoma

Mathias J Rummel, MD, PhD, Aline Tenzer, Norbert Niederle, MD, PhD, Chrisoph Losem, MD, PhD, Christina Balser, MD, PhD, Harald-E. Balló, MD, PhD, Manfred Welslau, MD, PhD, Ulrich von Grünhagen, MD, PhD, Wolfram Brugger, MD, PhD, Georg Maschmeyer, MD, PhD, Axel C. Matzdorff, MD, PhD, Arnold Ganser, MD, PhD, Eckhart Weidmann, MD, PhD, Gerhard Heil, MD, PhD, Axel Hinke, Jürgen Barth

Blood (2010) 116 (21): 3090.

https://doi.org/10.1182/blood.V116.21.3090.3090

Published: 2010

Journal Articles

Quantitative Real-Time PCR of Peripheral Blood t(14;18) Positive Cells Predicts Treatment Response and Long-Term Outcome in Patients with Follicular Lymphoma.

Fabian Zohren, Ingmar Bruns, MD, PhD, Juergen Barth, Sabrina Pechtel, Roland Fenk, Thomas Schroeder, Akos G. Czibere, MD, Georg Maschmeyer, Dorothea Kofahl-Krause, Gerhard Heil, Norbert Niederle, Christoph Losem, Manfred Welslau, Ulrich Germing, Ralf Kronenwett, Rainer Haas, Mathias J Rummel, MD, PhD, Guido Kobbe, MD

Blood (2009) 114 (22): 441.

https://doi.org/10.1182/blood.V114.22.441.441

Published: 2009

Journal Articles

Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Mathias J Rummel, MD, PhD, Norbert Niederle, Georg Maschmeyer, Andre Banat, MD, MBA, Ulrich von Gruenhagen, MD, Christoph Losem, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Harald Ballo, Eckhart Weidmann, Heinz A Duerk, Dorothea Kofahl-Krause, Fritz Roller, Juergen Barth, Dieter Hoelzer, MD, PhD, Axel Hinke, Wolfram Brugger

Blood (2009) 114 (22): 405.

https://doi.org/10.1182/blood.V114.22.405.405

Published: 2009

Journal Articles

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Study Group Indolent Lymphomas (StiL)

Mathias J Rummel, Ulrich von Gruenhagen, Norbert Niederle, Harald Ballo, Eckhart Weidmann, Manfred Welslau, Gerhard Heil, Christina Balser, Heinz A Duerk, Martina Stauch, Dorothea Kofahl-Krause, Ulrich Kaiser, Wolfgang Knauf, Wolfram Brugger, MD

Blood (2008) 112 (11): 2596.

https://doi.org/10.1182/blood.V112.11.2596.2596

Published: 2008

NARROW

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy

Subanalysis of the StiL NHL 1–2003 Study: Achievement of Complete Response with Bendamustine-Rituximab (B-R) and CHOP-R in the First-Line Treatment of Indolent and Mantle Cell Lymphomas Results in Superior Survival Compared to Partial Response.

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

No Elevated Rates of Treatment-Related Myelodysplastic Syndromes and Second Solid Tumors Following Therapy with Bendamustine Compared with Other Anti-Lymphoma Regimes for Low-Grade Non-Hodgkin's Lymphoma

Quantitative Real-Time PCR of Peripheral Blood t(14;18) Positive Cells Predicts Treatment Response and Long-Term Outcome in Patients with Follicular Lymphoma.

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Study Group Indolent Lymphomas (StiL)

Email alerts

ASH Publications

American Society of Hematology

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy

Subanalysis of the StiL NHL 1–2003 Study: Achievement of Complete Response with Bendamustine-Rituximab (B-R) and CHOP-R in the First-Line Treatment of Indolent and Mantle Cell Lymphomas Results in Superior Survival Compared to Partial Response.

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

No Elevated Rates of Treatment-Related Myelodysplastic Syndromes and Second Solid Tumors Following Therapy with Bendamustine Compared with Other Anti-Lymphoma Regimes for Low-Grade Non-Hodgkin's Lymphoma

Quantitative Real-Time PCR of Peripheral Blood t(14;18) Positive Cells Predicts Treatment Response and Long-Term Outcome in Patients with Follicular Lymphoma.

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Study Group Indolent Lymphomas (StiL)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only